found patients with increased tumor infiltrating leukocytes (TIL) responded more favorably to trastuzumab, suggesting that TILs may serve as a biomarker to identify which HER2 + breast cancer patients would most benefit from trastuzumab [16]. This evidence concerns the gene ERBB2 and neoplasm.